Cargando…

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells

BACKGROUND: Anti-apoptotic BCL-2 family members antagonise apoptosis by sequestering their pro-apoptotic counterparts. The balance between the different BCL-2 family members forms the basis of BH3 profiling, a peptide-based technique used to predict chemosensitivity of cancer cells. Recent identific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butterworth, Michael, Pettitt, Andrew, Varadarajan, Shankar, Cohen, Gerald M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800304/ https://www.ncbi.nlm.nih.gov/pubmed/26954718 http://dx.doi.org/10.1038/bjc.2016.49

Ejemplares similares

DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis
por: Milani, Mateus, et al.
Publicado: (2017)

BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma
por: Bodet, L, et al.
Publicado: (2010)

Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies
por: Al-Zebeeby, Aoula, et al.
Publicado: (2019)

Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck
por: Carter, Rachel J., et al.
Publicado: (2019)

Mitochondrial apoptosis and BH3 mimetics
por: Dai, Haiming, et al.
Publicado: (2016)

BH3 Mimetics in Hematologic Malignancies
por: Klener, Pavel, et al.
Publicado: (2021)

DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis
por: Milani, Mateus, et al.
Publicado: (2019)

Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
por: Koessinger, Anna L., et al.
Publicado: (2022)

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)

On BH3 Mimetics and Ca(2+) Signaling
por: Ferdek, Pawel E., et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

BH3 Mimetics for the Treatment of Prostate Cancer
por: Wolf, Philipp
Publicado: (2017)

The application of BH3 mimetics in myeloid leukemias
por: Parry, Narissa, et al.
Publicado: (2021)

Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
por: Potter, Danielle S., et al.
Publicado: (2021)

Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models
por: Olesinski, Elyse A., et al.
Publicado: (2021)

The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2015)

BH3-mimetics: recent developments in cancer therapy
por: Townsend, Paul A., et al.
Publicado: (2021)

Sensitivity of canine hematological cancers to BH3 mimetics
por: Jegatheeson, Selvi, et al.
Publicado: (2022)

Hypericin, a potential new BH3 mimetic
por: Doroshenko, Anastasia, et al.
Publicado: (2022)

The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization
por: Stamelos, Vasileios A., et al.
Publicado: (2016)

Overcoming EMT-driven therapeutic resistance by BH3 mimetics
por: Keitel, Ulrike, et al.
Publicado: (2014)

Defining the susceptibility of colorectal cancers to BH3-mimetic compounds
por: Luo, Ming-Jie, et al.
Publicado: (2020)

Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
por: Montero, Joan, et al.
Publicado: (2022)

Computational modeling of DLBCL predicts response to BH3-mimetics
por: Cloete, Ielyaas, et al.
Publicado: (2023)

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics
por: Fraser, Cameron S., et al.
Publicado: (2022)

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
por: Mukherjee, Nabanita, et al.
Publicado: (2018)

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
por: Jullien, Maxime, et al.
Publicado: (2020)

Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
por: Jacob, Maureen, et al.
Publicado: (2023)

Inhibition of the Anti-Apoptotic Bcl-2 Family by BH3 Mimetics Sensitize the Mitochondrial Permeability Transition Pore Through Bax and Bak
por: Patel, Pooja, et al.
Publicado: (2021)

BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X(L)
por: Greaves, Georgia, et al.
Publicado: (2018)

The Growing Role of the BH3 Mimetic Drug Venetoclax in the Therapy of Acute Myeloid Leukemia
por: Pelosi, Elvira, et al.
Publicado: (2022)

BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells
por: Reinhart, Ramona, et al.
Publicado: (2018)

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022)

BH3 profiling discriminates the anti-apoptotic status of 5-fluorouracil-resistant colon cancer cells
por: Ishikawa, Kazuma, et al.
Publicado: (2019)

A beam destination read-out for BH3∕BH4
por: Tanke, E
Publicado: (1984)

Interface de controle de BH3 et BH4
por: Liénard, P
Publicado: (1984)

Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
por: Pallis, Monica, et al.
Publicado: (2016)

Characterisation of the anti-apoptotic function of survivin-ΔEx3 during TNFα−mediated cell death
por: Malcles, M-H, et al.
Publicado: (2007)

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
por: Bieghs, Liesbeth, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4irod4fqqhfj14s1ihujm4pgbs